^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Ampulla of Vater Carcinoma
    Drug:Imfinzi (durvalumab) (PD-L1 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    Source:
    NCCN
    Published date:
    04/27/2023
    Excerpt:
    Ampullary Adenocarcinoma...Good PS….Pancreatobiliary/Mixed Type….Gemcitabine + cisplatin + durvalumab
    Secondary therapy:
    cisplatin + gemcitabine